Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
- [Stability of Reconstituted Peptide Formulations Under Refrigerated Storage]( *International Journal of Pharmaceutical Compounding*, 2023
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
The Pharmacist Guide to Assigning a Beyond-Use Date to a Compounded Sterile or Nonsterile Preparation (PDF)
What Results Should Patients Expect
This is a great question, and the short answer is yes, but not at the same time
2025 Jun 11
